284 related articles for article (PubMed ID: 19509254)
1. Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells.
Beharry Z; Zemskova M; Mahajan S; Zhang F; Ma J; Xia Z; Lilly M; Smith CD; Kraft AS
Mol Cancer Ther; 2009 Jun; 8(6):1473-83. PubMed ID: 19509254
[TBL] [Abstract][Full Text] [Related]
2. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.
Lin YW; Beharry ZM; Hill EG; Song JH; Wang W; Xia Z; Zhang Z; Aplan PD; Aster JC; Smith CD; Kraft AS
Blood; 2010 Jan; 115(4):824-33. PubMed ID: 19965690
[TBL] [Abstract][Full Text] [Related]
3. Cell-permeable carboxyl-terminal p27(Kip1) peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase.
Morishita D; Takami M; Yoshikawa S; Katayama R; Sato S; Kukimoto-Niino M; Umehara T; Shirouzu M; Sekimizu K; Yokoyama S; Fujita N
J Biol Chem; 2011 Jan; 286(4):2681-8. PubMed ID: 21062737
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases.
Dakin LA; Block MH; Chen H; Code E; Dowling JE; Feng X; Ferguson AD; Green I; Hird AW; Howard T; Keeton EK; Lamb ML; Lyne PD; Pollard H; Read J; Wu AJ; Zhang T; Zheng X
Bioorg Med Chem Lett; 2012 Jul; 22(14):4599-604. PubMed ID: 22727640
[TBL] [Abstract][Full Text] [Related]
5. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels.
Morishita D; Katayama R; Sekimizu K; Tsuruo T; Fujita N
Cancer Res; 2008 Jul; 68(13):5076-85. PubMed ID: 18593906
[TBL] [Abstract][Full Text] [Related]
6. PIM-1 kinase inhibitor SMI-4a exerts antitumor effects in chronic myeloid leukemia cells by enhancing the activity of glycogen synthase kinase 3β.
Fan RF; Lu Y; Fang ZG; Guo XY; Chen YX; Xu YC; Lei YM; Liu KF; Lin DJ; Liu LL; Liu XF
Mol Med Rep; 2017 Oct; 16(4):4603-4612. PubMed ID: 28849186
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes.
Mumenthaler SM; Ng PY; Hodge A; Bearss D; Berk G; Kanekal S; Redkar S; Taverna P; Agus DB; Jain A
Mol Cancer Ther; 2009 Oct; 8(10):2882-93. PubMed ID: 19825806
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel (+)-Usnic acid derivatives as potential anti-leukemia agents with pan-Pim kinases inhibitory activity.
Wang S; Zang J; Huang M; Guan L; Xing K; Zhang J; Liu D; Zhao L
Bioorg Chem; 2019 Aug; 89():102971. PubMed ID: 31200288
[TBL] [Abstract][Full Text] [Related]
9. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
Yang Q; Chen LS; Neelapu SS; Miranda RN; Medeiros LJ; Gandhi V
Blood; 2012 Oct; 120(17):3491-500. PubMed ID: 22955922
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases.
Xia Z; Knaak C; Ma J; Beharry ZM; McInnes C; Wang W; Kraft AS; Smith CD
J Med Chem; 2009 Jan; 52(1):74-86. PubMed ID: 19072652
[TBL] [Abstract][Full Text] [Related]
11. Rational Design of a Potent Pan-Pim Kinases Inhibitor with a Rhodanine-Benzoimidazole Structure.
Sawaguchi Y; Yamazaki R; Nishiyama Y; Sasai T; Mae M; Abe A; Yaegashi T; Nishiyama H; Matsuzaki T
Anticancer Res; 2017 Aug; 37(8):4051-4057. PubMed ID: 28739687
[TBL] [Abstract][Full Text] [Related]
12. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
[TBL] [Abstract][Full Text] [Related]
13. Identification of stemonamide synthetic intermediates as a novel potent anticancer drug with an apoptosis-inducing ability.
Li YY; Wang YY; Taniguchi T; Kawakami T; Baba T; Ishibashi H; Mukaida N
Int J Cancer; 2010 Jul; 127(2):474-84. PubMed ID: 19921695
[TBL] [Abstract][Full Text] [Related]
14. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.
Keeton EK; McEachern K; Dillman KS; Palakurthi S; Cao Y; Grondine MR; Kaur S; Wang S; Chen Y; Wu A; Shen M; Gibbons FD; Lamb ML; Zheng X; Stone RM; Deangelo DJ; Platanias LC; Dakin LA; Chen H; Lyne PD; Huszar D
Blood; 2014 Feb; 123(6):905-13. PubMed ID: 24363397
[TBL] [Abstract][Full Text] [Related]
15. [The role of mitogen-activated protein kinase cascades in inhibition of proliferation in human prostate carcinoma cells by raloxifene: an in vitro experiment].
Zhang YX; Kong CZ
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):271-5. PubMed ID: 18361842
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of quinoline derivatives as potential anti-prostate cancer agents and Pim-1 kinase inhibitors.
Li K; Li Y; Zhou D; Fan Y; Guo H; Ma T; Wen J; Liu D; Zhao L
Bioorg Med Chem; 2016 Apr; 24(8):1889-97. PubMed ID: 26979485
[TBL] [Abstract][Full Text] [Related]
17. PIM kinase inhibitors downregulate STAT3(Tyr705) phosphorylation.
Chang M; Kanwar N; Feng E; Siu A; Liu X; Ma D; Jongstra J
Mol Cancer Ther; 2010 Sep; 9(9):2478-87. PubMed ID: 20667852
[TBL] [Abstract][Full Text] [Related]
18. Pim kinase inhibitory and antiproliferative activity of a novel series of meridianin C derivatives.
More KN; Jang HW; Hong VS; Lee J
Bioorg Med Chem Lett; 2014 Jun; 24(11):2424-8. PubMed ID: 24775304
[TBL] [Abstract][Full Text] [Related]
19. 2-Thioxothiazolidin-4-one Analogs as Pan-PIM Kinase Inhibitors.
Yun Y; Hong VS; Jeong S; Choo H; Kim S; Lee J
Chem Pharm Bull (Tokyo); 2021; 69(9):854-861. PubMed ID: 34470949
[TBL] [Abstract][Full Text] [Related]
20. Aminothiazolones as potent, selective and cell active inhibitors of the PIM kinase family.
Quevedo CE; Bataille CJR; Byrne S; Durbin M; Elkins J; Guillermo A; Jones AM; Knapp S; Nadali A; Walker RG; Wilkinson IVL; Wynne GM; Davies SG; Russell AJ
Bioorg Med Chem; 2020 Nov; 28(22):115724. PubMed ID: 33128909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]